Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
Relapsed CLL responds to rapid venetoclax dose-escalation
Awan F et al. European Hematology Association 2018 Annual Congress. Abstract PF357
Key clinical point: CLL relapsed after therapy with a B-cell receptor signaling inhibitor has a rapidly progressive course, requiring quick ramp up of venetoclax.
Major finding: All patients reached the target dose of venetoclax, with only two cases of manageable clinical tumor lysis syndrome.
Study details: Retrospective analysis of outcomes for 15 patients with chronic lymphocytic leukemia relapsed after treatment with a B-cell receptor signaling inhibitor.
Disclosures: The study was internally funded. Dr. Awan receives research funding from Gilead, Pharmacyclics. AbbVie and Janssen.
Source: Awan F et al. European Hematology Association 2018 Annual Congress. Abstract PF357
Awan F et al. European Hematology Association 2018 Annual Congress. Abstract PF357